Gene Therapy improves functional measures in XLRP
Beacon Therapeutics announced positive results from their phase 2 gene therapy trial for X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.
Search
Search results
Positive early findings from ProQR trial of USH2A therapy
Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.
Giving in memory
Celebrate the life of your loved one, by donating in their memory and help us fund more research and support, now.
Meet our community: The Kearney family
Emily Kearney is mum to four boys, aged four to 13, two of whom are living with an inherited sight loss condition.
Discover Wellbeing
We have created Discover Wellbeing to help people affected by inherited sight loss to develop an awareness of emotional wellbeing and the practical skills to adapt to life’s ups and downs.
How we can work together
We can provide all the support your organisation needs to work with us; from ideas to practical support and materials. The Retina UK team will help your contribution be as fun and rewarding as possible.
Webinar: Looking after your emotional health
Retina UK recently launched an innovative course, Discover Wellbeing, to help those living with inherited sight loss develop an awareness of emotional wellbeing and practical skills to adapt to life’s ups and downs.
Potential drug targets identified for RP
A recently published study has described numerous disease mechanisms that appear to be common across different types of inherited sight loss, suggesting that there is significant potential for drug treatments that could work regardless of the underlying causative gene.
Retina UK-funded discovery leads to $2.5 award for further research
A discovery made as part of research funded by Retina UK has led to a prestigious award of $2.5 million, enabling scientists to undertake more in-depth investigations and work towards a treatment for a particular type of retinitis pigmentosa.
Meira GTx announces positive data from phase clinical trial
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.